Simplex Trading
CRVS icon

Simplex Trading’s Corvus Pharmaceuticals CRVS Stock Holding History

Simplex Trading’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Buy
92,343
+57,620
+166% +$800K ﹤0.01% 2416
2026
Q1 		$508K Buy
+34,723
New +$554K ﹤0.01% 3247
2025
Q2 		– Sell
-26,990
Closed -$98.2K – 8793
2025
Q1 		$85K Sell
26,990
-112,943
-81% -$532K ﹤0.01% 5218
2024
Q4 		$748K Buy
139,933
+134,263
+2,368% +$1M ﹤0.01% 3141
2024
Q3 		$29K Buy
5,670
+3,458
+156% +$12.4K ﹤0.01% 6371
2024
Q2 		$4K Sell
2,212
-7,134
-76% -$13.3K ﹤0.01% 7966
2024
Q1 		$16K Sell
9,346
-40,285
-81% -$84.1K ﹤0.01% 7252
2023
Q4 		$87K Buy
49,631
+10,138
+26% +$14.8K ﹤0.01% 5525
2023
Q3 		$57K Buy
39,493
+27,964
+243% +$59.1K ﹤0.01% 5675
2023
Q2 		$26K Buy
+11,529
New +$24K ﹤0.01% 6488
2023
Q1 		– Sell
-21,419
Closed -$16.7K – 9171
2022
Q4 		$18K Buy
21,419
+5,369
+33% +$4.75K ﹤0.01% 6967
2022
Q3 		$13K Sell
16,050
-9,548
-37% -$9.11K ﹤0.01% 7975
2022
Q2 		$25K Buy
25,598
+5,524
+28% +$6.78K ﹤0.01% 7320
2022
Q1 		$32K Buy
+20,074
New +$36.8K ﹤0.01% 7691
2021
Q4 		– Sell
-199
Closed -$772 – 10587
2021
Q3 		$0 Hold
199
– – ﹤0.01% 9780
2021
Q2 		$0 Sell
199
-5,687
-97% -$15.7K ﹤0.01% 10117
2021
Q1 		$18K Buy
+5,886
New +$21.3K ﹤0.01% 7528
2020
Q4 		– Sell
-117
Closed -$471 – 8430
2020
Q3 		$0 Buy
+117
New +$467 ﹤0.01% 7870
2020
Q2 		– Sell
-146
Closed -$431 – 7697
2020
Q1 		$0 Buy
+146
New +$593 ﹤0.01% 7683

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Simplex Trading's CRVS Position: Q2 2026 in Review

Simplex Trading increased its Corvus Pharmaceuticals (CRVS) stake by 166% in Q2 2026, buying an estimated $800K and bringing the position to 92,343 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2416.

Simplex Trading first reported a position in CRVS in Q1 2020 and has held it in 19 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Simplex Trading held 92,343 shares of Corvus Pharmaceuticals worth $1.38M as of Q2 2026.
  • Simplex Trading bought 57,620 Corvus Pharmaceuticals shares in Q2 2026, an estimated $800K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #2416 holding.
  • Simplex Trading first reported a position in Corvus Pharmaceuticals in Q1 2020 and has held it in 19 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.